RxDoctor Payments Data

Karl Gebhard, MD

Family Medicine · Mission Viejo, CANPI 1548266018

Payments from drug & device makers

$4,760in general payments, 2019–2025

Across 213 payments — averaging $22.35 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$2K
  • Novo Nordisk$762
  • GSK$510
  • Lilly USA, LLC$208
  • Exact Sciences$198
  • Amgen$161
  • plus $1K from 20 others

What the payments were for

  • Food & beverage$4,760100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,760 in reported general payments places this provider in the 90th percentile of 10,533 family medicine providers in California.

See all family medicine providers in California

Medicare billing

Part B allowed, 2024
$115,943
Medicare patients
260
Services billed
1,227

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
FarxigaDapagliflozin Propanediol11$11,667
Levothyroxine Sodium95$1,292
Rosuvastatin Calcium63$1,106
Atorvastatin Calcium185$1,049
Albuterol Sulfate HfaAlbuterol Sulfate53$879
Testosterone11$777
Gabapentin43$758
Omeprazole48$667
Metoprolol Succinate42$547
Ezetimibe16$527
Ammonium Lactate14$518
Amlodipine Besylate112$470
Tamsulosin Hcl38$467
Simvastatin42$466
Losartan Potassium77$443

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaFarxiga$1,591$11,66711 claims
AbbVieSynthroid$141$21113 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 10,533 family medicine providers in California.

Other family medicine in Mission Viejo

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →